press release archive

Rigel to Present at the Adams Harkness 25th Annual Summer Seminar on Thursday, August 4th

SOUTH SAN FRANCISCO, Calif. - July 26, 2005

Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) will present at the 25th Annual Adams Harkness Summer Seminar on Thursday, August 4, 2005 at 2:00 p.m. EDT at the Marriott Long Wharf Hotel in Boston. Raul Rodriguez, Rigel’s executive vice president and chief operating officer, will discuss Rigel’s clinical trials addressing allergy and rheumatoid arthritis, as well as products currently in pre-clinical development.

To access the live audio webcast or the subsequent archived recording, log on to www.rigel.com/rigel/events. Please connect to Rigel's website several minutes prior to the start of the conference call to ensure adequate time for any software download that may be necessary.

About Rigel
Rigel's mission is to become a source of novel, small-molecule drugs to meet large, unmet medical needs. We have three product development programs: asthma/allergy, rheumatoid arthritis and cancer. Our strategy is to commence clinical trials with one lead compound each year and to develop a portfolio of product candidates for our own proprietary programs and with potential collaborative partners.

This press release contains "forward-looking" statements, including statements related to Rigel's plans to pursue clinical development of product candidates and the timing thereof and the potential efficacy of product candidates. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "plans," "intends," "expects" and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause Rigel's results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of pre-clinical studies and clinical trials, as well as other risks detailed from time to time in Rigel's SEC reports, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2005. Rigel does not undertake any obligation to update forward-looking statements.

Contact: Raul R. Rodriguez
Phone: 650.624.1302
Email: invrel@rigel.com